Medical - Care Facilities
Compare Stocks
4 / 10Stock Comparison
SEM vs DBVT vs ENSG vs ALKS
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
Medical - Care Facilities
Biotechnology
SEM vs DBVT vs ENSG vs ALKS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Medical - Care Facilities | Biotechnology | Medical - Care Facilities | Biotechnology |
| Market Cap | $2.04B | $1712.35T | $10.18B | $5.90B |
| Revenue (TTM) | $5.52B | $0.00 | $5.27B | $1.56B |
| Net Income (TTM) | $134M | $-168M | $363M | $153M |
| Gross Margin | 10.6% | — | 15.2% | 65.4% |
| Operating Margin | 5.8% | — | 8.5% | 12.3% |
| Forward P/E | 13.1x | — | 23.2x | 24.8x |
| Total Debt | $3.70B | $22M | $4.15B | $70M |
| Cash & Equiv. | $27M | $194M | $504M | $1.12B |
SEM vs DBVT vs ENSG vs ALKS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Select Medical Hold… (SEM) | 100 | 189.2 | +89.2% |
| DBV Technologies S.… (DBVT) | 100 | 41.2 | -58.8% |
| The Ensign Group, I… (ENSG) | 100 | 398.7 | +298.7% |
| Alkermes plc (ALKS) | 100 | 216.4 | +116.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SEM vs DBVT vs ENSG vs ALKS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
SEM is the #2 pick in this set and the best alternative if income & stability is your priority.
- Dividend streak 0 yrs, beta 0.46, yield 1.5%
- Lower P/E (13.1x vs 24.8x)
- 1.5% yield, vs ENSG's 0.1%, (2 stocks pay no dividend)
DBVT is the clearest fit if your priority is momentum.
- +110.4% vs SEM's +11.1%
ENSG carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 18.7%, EPS growth 14.1%, 3Y rev CAGR 18.7%
- 7.5% 10Y total return vs SEM's 158.5%
- Lower volatility, beta 0.42, current ratio 1.42x
- Beta 0.42, yield 0.1%, current ratio 1.42x
ALKS is the clearest fit if your priority is quality.
- 9.8% margin vs DBVT's 0.3%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 18.7% revenue growth vs DBVT's -100.0% | |
| Value | Lower P/E (13.1x vs 24.8x) | |
| Quality / Margins | 9.8% margin vs DBVT's 0.3% | |
| Stability / Safety | Beta 0.42 vs DBVT's 1.26 | |
| Dividends | 1.5% yield, vs ENSG's 0.1%, (2 stocks pay no dividend) | |
| Momentum (1Y) | +110.4% vs SEM's +11.1% | |
| Efficiency (ROA) | 6.8% ROA vs DBVT's -89.0% |
SEM vs DBVT vs ENSG vs ALKS — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
SEM vs DBVT vs ENSG vs ALKS — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
ALKS leads in 2 of 6 categories
SEM leads 1 • ENSG leads 1 • DBVT leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
ALKS leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
SEM and DBVT operate at a comparable scale, with $5.5B and $0 in trailing revenue. ALKS is the more profitable business, keeping 9.8% of every revenue dollar as net income compared to SEM's 2.4%. On growth, ALKS holds the edge at +28.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $5.5B | $0 | $5.3B | $1.6B |
| EBITDAEarnings before interest/tax | $465M | -$112M | $558M | $212M |
| Net IncomeAfter-tax profit | $134M | -$168M | $363M | $153M |
| Free Cash FlowCash after capex | $117M | -$151M | $406M | $392M |
| Gross MarginGross profit ÷ Revenue | +10.6% | — | +15.2% | +65.4% |
| Operating MarginEBIT ÷ Revenue | +5.8% | — | +8.5% | +12.3% |
| Net MarginNet income ÷ Revenue | +2.4% | — | +6.9% | +9.8% |
| FCF MarginFCF ÷ Revenue | +2.1% | — | +7.7% | +25.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | +5.0% | — | +18.4% | +28.2% |
| EPS Growth (YoY)Latest quarter vs prior year | -18.2% | +91.5% | +21.9% | -4.1% |
Valuation Metrics
SEM leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
At 13.9x trailing earnings, SEM trades at a 53% valuation discount to ENSG's 29.8x P/E. On an enterprise value basis, SEM's 12.0x EV/EBITDA is more attractive than ENSG's 25.7x.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $2.0B | $1712.35T | $10.2B | $5.9B |
| Enterprise ValueMkt cap + debt − cash | $5.7B | $1712.35T | $13.8B | $4.9B |
| Trailing P/EPrice ÷ TTM EPS | 13.93x | -0.76x | 29.85x | 24.76x |
| Forward P/EPrice ÷ next-FY EPS est. | 13.06x | — | 23.19x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | 2.16x | — |
| EV / EBITDAEnterprise value multiple | 12.04x | — | 25.71x | 17.25x |
| Price / SalesMarket cap ÷ Revenue | 0.37x | — | 2.01x | 4.00x |
| Price / BookPrice ÷ Book value/share | 1.00x | 0.66x | 4.59x | 3.28x |
| Price / FCFMarket cap ÷ FCF | 5.33x | — | 27.46x | 12.28x |
Profitability & Efficiency
ALKS leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
ENSG delivers a 16.6% return on equity — every $100 of shareholder capital generates $17 in annual profit, vs $-130 for DBVT. ALKS carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to ENSG's 1.86x. On the Piotroski fundamental quality scale (0–9), ALKS scores 7/9 vs DBVT's 4/9, reflecting strong financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | +6.6% | -130.2% | +16.6% | +8.8% |
| ROA (TTM)Return on assets | +2.3% | -89.0% | +6.8% | +5.4% |
| ROICReturn on invested capital | +4.8% | — | +7.0% | +18.9% |
| ROCEReturn on capital employed | +7.0% | -145.7% | +10.2% | +14.2% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 4 | 5 | 7 |
| Debt / EquityFinancial leverage | 1.82x | 0.13x | 1.86x | 0.04x |
| Net DebtTotal debt minus cash | $3.7B | -$172M | $3.7B | -$1.0B |
| Cash & Equiv.Liquid assets | $27M | $194M | $504M | $1.1B |
| Total DebtShort + long-term debt | $3.7B | $22M | $4.2B | $70M |
| Interest CoverageEBIT ÷ Interest expense | 4.41x | -189.82x | 88.33x | 32.30x |
Total Returns (Dividends Reinvested)
ENSG leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ENSG five years ago would be worth $20,324 today (with dividends reinvested), compared to $3,090 for DBVT. Over the past 12 months, DBVT leads with a +110.4% total return vs SEM's +11.1%. The 3-year compound annual growth rate (CAGR) favors ENSG at 23.6% vs SEM's 2.4% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | +11.4% | +4.9% | +0.3% | +25.3% |
| 1-Year ReturnPast 12 months | +11.1% | +110.4% | +27.5% | +16.5% |
| 3-Year ReturnCumulative with dividends | +7.4% | +19.7% | +88.9% | +14.5% |
| 5-Year ReturnCumulative with dividends | -11.1% | -69.1% | +103.2% | +60.9% |
| 10-Year ReturnCumulative with dividends | +158.5% | -87.0% | +752.0% | -11.0% |
| CAGR (3Y)Annualised 3-year return | +2.4% | +6.2% | +23.6% | +4.6% |
Risk & Volatility
Evenly matched — SEM and ENSG each lead in 1 of 2 comparable metrics.
Risk & Volatility
ENSG is the less volatile stock with a 0.42 beta — it tends to amplify market swings less than DBVT's 1.26 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. SEM currently trades 96.8% from its 52-week high vs DBVT's 76.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.46x | 1.26x | 0.42x | 1.06x |
| 52-Week HighHighest price in past year | $16.99 | $26.18 | $218.00 | $36.60 |
| 52-Week LowLowest price in past year | $11.65 | $7.53 | $133.81 | $25.17 |
| % of 52W HighCurrent price vs 52-week peak | +96.8% | +76.3% | +80.0% | +96.7% |
| RSI (14)Momentum oscillator 0–100 | 60.9 | 48.1 | 23.3 | 60.2 |
| Avg Volume (50D)Average daily shares traded | 2.1M | 252K | 358K | 2.3M |
Analyst Outlook
Evenly matched — SEM and ENSG each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: SEM as "Hold", DBVT as "Buy", ENSG as "Buy", ALKS as "Buy". Consensus price targets imply 131.8% upside for DBVT (target: $46) vs 9.5% for SEM (target: $18). For income investors, SEM offers the higher dividend yield at 1.55% vs ENSG's 0.14%.
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $18.00 | $46.33 | $222.33 | $44.00 |
| # AnalystsCovering analysts | 13 | 15 | 13 | 28 |
| Dividend YieldAnnual dividend ÷ price | +1.5% | — | +0.1% | — |
| Dividend StreakConsecutive years of raises | 0 | 0 | 12 | 0 |
| Dividend / ShareAnnual DPS | $0.25 | — | $0.24 | — |
| Buyback YieldShare repurchases ÷ mkt cap | +4.9% | 0.0% | +0.2% | +0.5% |
ALKS leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). SEM leads in 1 (Valuation Metrics). 2 tied.
SEM vs DBVT vs ENSG vs ALKS: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is SEM or DBVT or ENSG or ALKS a better buy right now?
For growth investors, The Ensign Group, Inc.
(ENSG) is the stronger pick with 18. 7% revenue growth year-over-year, versus -5. 2% for Alkermes plc (ALKS). Select Medical Holdings Corporation (SEM) offers the better valuation at 13. 9x trailing P/E (13. 1x forward), making it the more compelling value choice. Analysts rate DBV Technologies S. A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — SEM or DBVT or ENSG or ALKS?
On trailing P/E, Select Medical Holdings Corporation (SEM) is the cheapest at 13.
9x versus The Ensign Group, Inc. at 29. 8x. On forward P/E, Select Medical Holdings Corporation is actually cheaper at 13. 1x.
03Which is the better long-term investment — SEM or DBVT or ENSG or ALKS?
Over the past 5 years, The Ensign Group, Inc.
(ENSG) delivered a total return of +103. 2%, compared to -69. 1% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: ENSG returned +752. 0% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — SEM or DBVT or ENSG or ALKS?
By beta (market sensitivity over 5 years), The Ensign Group, Inc.
(ENSG) is the lower-risk stock at 0. 42β versus DBV Technologies S. A. 's 1. 26β — meaning DBVT is approximately 198% more volatile than ENSG relative to the S&P 500. On balance sheet safety, Alkermes plc (ALKS) carries a lower debt/equity ratio of 4% versus 186% for The Ensign Group, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — SEM or DBVT or ENSG or ALKS?
By revenue growth (latest reported year), The Ensign Group, Inc.
(ENSG) is pulling ahead at 18. 7% versus -5. 2% for Alkermes plc (ALKS). On earnings-per-share growth, the picture is similar: The Ensign Group, Inc. grew EPS 14. 1% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, ENSG leads at 18. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — SEM or DBVT or ENSG or ALKS?
Alkermes plc (ALKS) is the more profitable company, earning 16.
4% net margin versus 0. 0% for DBV Technologies S. A. — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALKS leads at 17. 2% versus 0. 0% for DBVT. At the gross margin level — before operating expenses — ALKS leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is SEM or DBVT or ENSG or ALKS more undervalued right now?
On forward earnings alone, Select Medical Holdings Corporation (SEM) trades at 13.
1x forward P/E versus 23. 2x for The Ensign Group, Inc. — 10. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DBVT: 131. 8% to $46. 33.
08Which pays a better dividend — SEM or DBVT or ENSG or ALKS?
In this comparison, SEM (1.
5% yield), ENSG (0. 1% yield) pay a dividend. DBVT, ALKS do not pay a meaningful dividend and should not be held primarily for income.
09Is SEM or DBVT or ENSG or ALKS better for a retirement portfolio?
For long-horizon retirement investors, Select Medical Holdings Corporation (SEM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
46), 1. 5% yield, +158. 5% 10Y return). Both have compounded well over 10 years (SEM: +158. 5%, DBVT: -87. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between SEM and DBVT and ENSG and ALKS?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: SEM is a small-cap deep-value stock; DBVT is a mega-cap quality compounder stock; ENSG is a mid-cap high-growth stock; ALKS is a small-cap quality compounder stock. SEM pays a dividend while DBVT, ENSG, ALKS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.